Skip to content

PharmAnt is the trusted news hub of the pharma sector

Recent Pharma Sector News

News
Rare Disorders
INTERVIEWS
TECH
Contact Us

Search for:

Home
Home
Home
European Commission approved Alnylam’s AMVUTTRA, an RNAi therapeutic for treating hATTR amyloidosis with polyneuropathy
Amvuttra.001

Amvuttra.001

Post navigation

Previous European Commission approved Alnylam’s AMVUTTRA, an RNAi therapeutic for treating hATTR amyloidosis with polyneuropathy

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Δ

Follow us

facebook
linkedin
twitter

Name*

Email*

Please leave this field empty.

My name is !

My Name is...Spinal Muscular Atrophy (SMA) August 14, 2021
My Name is ... Alström syndrome! April 17, 2021
My Name is .... Wilson's Disease! March 28, 2021
My Name is .... Alport Syndrome March 14, 2021
My Name is.... Acromegaly ! February 27, 2021

You may have missed

Home
Home
Rare Disorders

Understanding Lymphatic Malformations: A Comprehensive Overview

2 years ago admin

Epidermolysis Bullosa

Home
Rare Disorders

Understanding Epidermolysis Bullosa: A Devastating Skin Condition

2 years ago admin

Disease Overview: Duchenne muscular dystrophy

Home
Rare Disorders

Disease Overview: Duchenne Muscular Dystrophy

3 years ago Mona Al Absi

Promising Therapeutic Approaches for Spinal Muscular Atrophy (SMA)

Home
News
Rare Disorders

Promising Therapeutic Approaches for Spinal Muscular Atrophy (SMA)

3 years ago Mona Al Absi

PharmAnt© All rights reserved. | Newsphere by AF themes.